Carrimycin

{{Short description|Macrolide antibiotic}}

{{cs1 config|name-list-style=vanc|display-authors=6}}

{{Infobox drug

| drug_name =

| INN =

| type =

| image = Carrimycin.svg

| caption = Carrimycin mixture: R = H, acetyl, or propionyl

| pronounce =

| tradename = Bite

| Drugs.com =

| MedlinePlus =

| pregnancy_AU =

| pregnancy_AU_comment =

| pregnancy_category=

| routes_of_administration =

| ATCvet =

| ATC_prefix =

| ATC_suffix =

| legal_AU =

| legal_AU_comment =

| legal_BR =

| legal_BR_comment =

| legal_CA =

| legal_CA_comment =

| legal_DE =

| legal_DE_comment =

| legal_NZ =

| legal_NZ_comment =

| legal_UK =

| legal_UK_comment =

| legal_US =

| legal_US_comment =

| legal_EU =

| legal_EU_comment =

| legal_UN =

| legal_UN_comment =

| legal_status = Rx-only

| bioavailability =

| protein_bound =

| metabolism =

| metabolites =

| onset =

| elimination_half-life =

| duration_of_action=

| excretion =

| synonyms = Isovalerylspiramycin

| CAS_number =

| PubChem =

| UNII = K5E0V85NB9

| DrugBank = DB16476

| IUPAC_name =

| chemical_formula =

| molecular_weight =

}}

Carrimycin is a macrolide antibiotic. It was approved by the National Medical Products Administration of China in 2019.{{cite web | url = https://imb.com.cn/en/News/87b5a57c414d4c15a6d84e8aa75cf2ad.htm | title = Class I drug Carrimycin approved by National Medical Products Administration of China | date = July 5, 2019 | publisher = Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College }} It is approved for the treatment of acute tracheal bronchitis caused by Haemophilus influenzae, Streptococcus pneumoniae, and for the treatment of acute sinusitis caused by S. pneumoniae, H. influenzae, Streptococcus pyogenes, Moraxella catarrhalis, and Staphylococcus.{{cite journal | vauthors = Yan H, Sun J, Wang K, Wang H, Wu S, Bao L, He W, Wang D, Zhu A, Zhang T, Gao R, Dong B, Li J, Yang L, Zhong M, Lv Q, Qin F, Zhuang Z, Huang X, Yang X, Li Y, Che Y, Jiang J | title = Repurposing carrimycin as an antiviral agent against human coronaviruses, including the currently pandemic SARS-CoV-2 | journal = Acta Pharmaceutica Sinica. B | volume = 11 | issue = 9 | pages = 2850–2858 | date = September 2021 | pmid = 33723501 | pmc = 7946546 | doi = 10.1016/j.apsb.2021.02.024 }} Carrimycin is mainly used for the treatment of upper respiratory tract infections.

Carrimycin is a mixture of related chemical compounds, carrimycin I through III, which are each ester derivatives of spiramycin.{{cite journal | vauthors = Yu LC, Dang DD, Zhuang S, Chen S, Zhuang Z, Rosenblum JS | title = Carrimycin, a first in-class anti-cancer agent, targets selenoprotein H to induce nucleolar oxidative stress and inhibit ribosome biogenesis | journal = Cancer Pathogenesis and Therapy | volume = 1 | issue = 2 | pages = 111–115 | date = April 2023 | pmid = 37750087 | doi = 10.1016/j.cpt.2022.12.005 | pmc = 10518895 }}

Carrimycin has also been investigated for the treatment of COVID-19.{{cite journal | vauthors = Al-Horani RA, Kar S, Aliter KF | title = Potential Anti-COVID-19 Therapeutics that Block the Early Stage of the Viral Life Cycle: Structures, Mechanisms, and Clinical Trials | journal = International Journal of Molecular Sciences | volume = 21 | issue = 15 | page = 5224 | date = July 2020 | pmid = 32718020 | doi = 10.3390/ijms21155224 | doi-access = free | pmc = 7432953 }}